Synapse - Maura Dickler

Search Within

Maura N Dickler

Results (263)

Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up

Journal Article

Wen, H. Y.; Krystel-Whittemore, M.; Patil, S.; Pareja, F.; Bowser, Z. L.; Dickler, M. N.; Norton, L.; Morrow, M.; Hudis, C. A.; Brogi, E.
Cancer (2017)

Fulltext@MSK | Save

Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study

Meeting Abstract

Li, D.; Dickler, M. N.; McCall, L. M.; Hahn, O. M.; Nudis, C. A.; Cohen, H. J.; Muss, H. B.; Ballman, K. V.; Winer, E. P.; Tripathy, D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503

Meeting Abstract

Innocenti, F.; Owzar, K.; Jiang, C.; Sibley, A.; Mulkey, F.; Carey, L. A.; Tripathy, D.; Schneider, B. P.; Barry, W. T.; Winer, E. P.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for advanced disease

Meeting Abstract

Dickler, M. N.; Tolaney, S. M.; Rugo, H. S.; Cortes, J.; Dieras, V.; Patt, D. A.; Wildiers, H.; Frenzel, M.; Koustenis, A.; Baselga, J.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR+) advanced breast cancer (BC)

Meeting Abstract

Dickler, M. N.; Saura, C.; Richards, D. A.; Krop, I. E.; Cervantes, A.; Bedard, P. L.; Patel, M. R.; Pusztai, L.; Oliveira, M.; Ware, J. A.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)

Meeting Abstract

Tolaney, S. M.; Cortes, J.; Dickler, M. N.; Zamora, E.; Caldwell, C. W.; Nguyen, T. S.; Nanda, S.; Koustenis, A.; Rugo, H. S.
Annals of Oncology (2016)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer

Meeting Abstract

Beeram, M.; Tolaney, S. M.; Beck, J. T.; Dickler, M. N.; Conlin, A. K.; Dees, C.; Helsten, T. L.; Conkling, P. R.; Edenfield, W. J.; Richards, D. A.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Endocrine resistance in hormone-responsive breast cancer: Mechanisms and therapeutic strategies

Journal Article

Murphy, C. G.; Dickler, M. N.
Endocrine-Related Cancer (2016)

Fulltext@MSK | Save

PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition

Journal Article

Castel, P.; Ellis, H.; Bago, R.; Toska, E.; Razavi, P.; Carmona, F. J.; Kannan, S.; Verma, C. S.; Dickler, M.; Chandarlapaty, S.; more...
Cancer Cell (2016)

Fulltext@MSK | Save